{
  "zip": "T2P 3P2",
  "sector": "Healthcare",
  "longBusinessSummary": "Zenith Capital Corp., a biotechnology investment company, develops bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. Its lead compound ZEN-3694 which is in phase II clinical trials for the treatment of metastatic castration resistant prostate cancer and in a phase 1b/2 clinical trial for triple negative breast cancer. The company was incorporated in 2013 and is based in Calgary, Canada.",
  "city": "Calgary",
  "state": "AB",
  "country": "Canada",
  "companyOfficers": [],
  "website": "http://www.zenithepigenetics.com",
  "maxAge": 1,
  "address1": "815 - 8th Avenue SW",
  "industry": "Biotechnology",
  "address2": "Suite 600",
  "previousClose": 0.36,
  "regularMarketOpen": 0.355,
  "twoHundredDayAverage": null,
  "trailingAnnualDividendYield": null,
  "payoutRatio": 0,
  "volume24Hr": null,
  "regularMarketDayHigh": 0.52,
  "navPrice": null,
  "averageDailyVolume10Day": null,
  "totalAssets": null,
  "regularMarketPreviousClose": 0.36,
  "fiftyDayAverage": null,
  "trailingAnnualDividendRate": null,
  "open": 0.355,
  "averageVolume10days": null,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": null,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 0.355,
  "priceHint": 4,
  "currency": "USD",
  "regularMarketVolume": 24258,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 34546596,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": null,
  "priceToSalesTrailing12Months": null,
  "dayLow": 0.355,
  "ask": null,
  "ytdReturn": null,
  "askSize": null,
  "volume": 24258,
  "fiftyTwoWeekHigh": 0.52,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 0.355,
  "bid": null,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": null,
  "dayHigh": 0.52,
  "exchange": "PNK",
  "shortName": "ZENITH CAPITAL CORPORATION",
  "longName": "Zenith Capital Corp.",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "ZHCLF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_241124088",
  "uuid": "be5296e4-88dc-334d-8632-85bbc7213e72",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": 0,
  "enterpriseToEbitda": -6.928,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 134991008,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": null,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1588204800,
  "heldPercentInstitutions": null,
  "netIncomeToCommon": -8728000,
  "trailingEps": null,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": null,
  "heldPercentInsiders": null,
  "nextFiscalYearEnd": 1651276800,
  "mostRecentQuarter": 1604102400,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 114079097,
  "enterpriseValue": 57015748,
  "threeYearAverageReturn": null,
  "lastSplitDate": null,
  "lastSplitFactor": null,
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 0.355,
  "logo_url": "https://logo.clearbit.com/zenithepigenetics.com"
}